Annuncio • Feb 04
Medexus Pharmaceuticals Inc. to Report Q3, 2026 Results on Feb 11, 2026 Medexus Pharmaceuticals Inc. announced that they will report Q3, 2026 results at 4:00 PM, US Eastern Standard Time on Feb 11, 2026 Annuncio • Nov 06
Medexus Pharmaceuticals Inc. to Report Q2, 2026 Results on Nov 12, 2025 Medexus Pharmaceuticals Inc. announced that they will report Q2, 2026 results After-Market on Nov 12, 2025 Annuncio • Aug 06
Medexus Pharmaceuticals Inc. to Report Q1, 2026 Results on Aug 12, 2025 Medexus Pharmaceuticals Inc. announced that they will report Q1, 2026 results After-Market on Aug 12, 2025 Annuncio • Jul 22
Medexus Pharmaceuticals Inc., Annual General Meeting, Sep 25, 2025 Medexus Pharmaceuticals Inc., Annual General Meeting, Sep 25, 2025. Annuncio • Jun 18
Medexus Pharmaceuticals Inc. to Report Q4, 2025 Results on Jun 25, 2025 Medexus Pharmaceuticals Inc. announced that they will report Q4, 2025 results After-Market on Jun 25, 2025 Annuncio • Feb 02
Medexus Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of CAD 30 million. Medexus Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of CAD 30 million.
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 6,000,000
Price\Range: CAD 4
Discount Per Security: CAD 0.24
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 1,500,000
Price\Range: CAD 4
Discount Per Security: CAD 0.12
Transaction Features: Rule 144A Annuncio • Feb 01
Medexus Pharmaceuticals Inc. to Report Q3, 2025 Results on Feb 05, 2025 Medexus Pharmaceuticals Inc. announced that they will report Q3, 2025 results After-Market on Feb 05, 2025 Annuncio • Jan 29
Medexus Pharmaceuticals Inc. has filed a Follow-on Equity Offering. Medexus Pharmaceuticals Inc. has filed a Follow-on Equity Offering.
Security Name: Common Shares
Security Type: Common Stock
Transaction Features: Rule 144A Annuncio • Nov 21
Medexus and pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Trecondyv (treosulfan for injection) in Canada Earlier in November 2024, Medexus Pharmaceuticals successfully completed a negotiation process with the pan-Canadian Pharmaceutical Alliance seeking to make Trecondyv® (treosulfan for injection) accessible to publicly funded drug programs and patients in Canada. The pCPA is an independent organization whose membership includes the provincial, territorial, and federal governments. Reaching this important milestone on November 4, 2024 was the result of a collaborative negotiation process with pCPA,¹ and followed publication of final recommendations on reimbursement from Québec's L'Institut National d'Excellence en Santé et en Services Sociaux on March 6, 2024 and from Canada's Drug Agency (formerly CADTH) on March 18, 2024, based on Medexus's July 2023 submissions to those agencies. The next step in the public reimbursement process will be for participating government organizations to
make their respective final decisions on public reimbursement for their regions. Medexus is committed to continuing to work with participating provincial, territorial, and federal government organizations to make Trecondyv® available as soon as possible through public drug plans for the patients who need it. Annuncio • Oct 30
Medexus Pharmaceuticals Inc. to Report Q2, 2025 Results on Nov 07, 2024 Medexus Pharmaceuticals Inc. announced that they will report Q2, 2025 results After-Market on Nov 07, 2024 Annuncio • Jul 31
Medexus Pharmaceuticals Inc. to Report Q1, 2025 Results on Aug 07, 2024 Medexus Pharmaceuticals Inc. announced that they will report Q1, 2025 results After-Market on Aug 07, 2024 Annuncio • Jul 16
Medexus Pharmaceuticals Inc., Annual General Meeting, Sep 19, 2024 Medexus Pharmaceuticals Inc., Annual General Meeting, Sep 19, 2024. Annuncio • Jun 19
Medexus Pharmaceuticals Inc. to Report Q4, 2024 Results on Jun 25, 2024 Medexus Pharmaceuticals Inc. announced that they will report Q4, 2024 results After-Market on Jun 25, 2024 Annuncio • Jun 08
Medexus Pharmaceuticals Inc. Announces FDA Accepts for Review Treosulfan NDA Medexus Pharmaceuticals was informed by medac that the US Food and Drug Administration has accepted for review medac's April 2024 resubmission of the New Drug Application for treosulfan. Medexus expects that the FDA will complete its review of the treosulfan NDA and issue a decision by October 30, 2024. The treosulfan NDA seeks approval of treosulfan in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients. medac's resubmission provided additional information that had previously been requested by the FDA relating to the pivotal phase 3 clinical trial of treosulfan conducted by medac. Medexus successfully launched treosulfan in Canada under the brand name Trecondyv® in September 2021, and since launch has gained valuable experience commercializing the product in that market. This success in Canada supports Medexus's optimism regarding treosulfan's potential positive impact in the US market if and when approved. Under the terms of a September 2023 amendment to Medexus's February 2021 exclusive license agreement relating to commercialization of treosulfan in the United States, Medexus and medac now have a specified negotiation period to agree to a further amendment with respect to any adjustments to the value of unpaid regulatory and sales-based milestone payments that the parties may agree are appropriate in the prevailing circumstances. Medexus will have no obligation to make any milestone payments before the effective date of any such further amendment to the US treosulfan agreement. Annuncio • Jan 31
Medexus Pharmaceuticals Inc. to Report Q3, 2024 Results on Feb 07, 2024 Medexus Pharmaceuticals Inc. announced that they will report Q3, 2024 results After-Market on Feb 07, 2024 Annuncio • Jan 09
Medexus Pharmaceuticals Announces Health Canada Accepts for Review Medexus's New Drug Submission, or NDS, for Terbinafine Hydrochloride Nail Lacquer to Treat fungal N Infections Medexus Pharmaceuticals announced that Health Canada recently accepted for review Medexus's new drug submission, or NDS, for terbinafine hydrochloride nail lacquer to treat fungal nail infections. Medexus's NDS for topical terbinafine seeks Health Canada approval for a distinctive once-a week treatment regimen. If and when approved, the product will enter the Canadian topical fungicides market that is estimated to be CAD 88 million on an annual basis. Annuncio • Nov 02
Medexus Pharmaceuticals Inc. to Report Q2, 2024 Results on Nov 08, 2023 Medexus Pharmaceuticals Inc. announced that they will report Q2, 2024 results After-Market on Nov 08, 2023 Annuncio • Oct 07
Medexus Pharmaceuticals Inc. has completed a Composite Units Offering in the amount of CAD 10.000205 million. Medexus Pharmaceuticals Inc. has completed a Composite Units Offering in the amount of CAD 10.000205 million.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 3,389,900
Price\Range: CAD 2.95
Discount Per Security: CAD 0.177 Annuncio • Aug 18
Medexus Pharmaceuticals Announces the Presentation of Data from Phase 3/4 Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of IXINITY Medexus Pharmaceuticals Inc. announced the presentation of data from a Phase 3/4 study that evaluated the pharmacokinetics (PK), safety, and efficacy of IXINITY, an intravenous recombinant factor IX therapeutic, as a prophylactic treatment in previously treated pediatric patients under 12 years of age with severe or moderately severe hemophilia B, a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood. In a poster presentation at the National Hemophilia Foundation (NHF) Bleeding Disorders Conference 2023 in National Harbor, Maryland, researchers reported that prophylaxis with IXINITY was associated with low annualized bleeding rates (ABRs), effective control of bleeding episodes, consistent PK, and a consistent safety profile. IXINITY is currently approved for use in patients 12 years of age or older with hemophilia B. Annuncio • Aug 03
Medexus Pharmaceuticals Inc. to Report Q1, 2024 Results on Aug 09, 2023 Medexus Pharmaceuticals Inc. announced that they will report Q1, 2024 results After-Market on Aug 09, 2023 Annuncio • Jul 15
Medexus Pharmaceuticals Inc., Annual General Meeting, Sep 21, 2023 Medexus Pharmaceuticals Inc., Annual General Meeting, Sep 21, 2023. Annuncio • Jun 15
Medexus Pharmaceuticals Inc. to Report Q4, 2023 Results on Jun 21, 2023 Medexus Pharmaceuticals Inc. announced that they will report Q4, 2023 results After-Market on Jun 21, 2023 Annuncio • Jun 14
Medexus Pharmaceuticals Presents Positive New Data on Treosulfan That Researchers At Toronto's Princess Margaret Hospital Recently Presented At Mds 2023 Medexus Pharmaceuticals Inc. announced to highlight positive new data on treosulfan that researchers at Toronto's Princess Margaret Hospital (PMH) recently presented at MDS 2023, the 17th annual International Congress on Myelodysplastic Syndromes, held in Marseille, France. The study, a retrospective analysis of patient outcomes, further confirms Medexus's optimism regarding treosulfan's potential positive impact in both Canada and the United States. The MDS 2023 presentation is substantially consistent with the previously published final study results and analysis of the pivotal phase 3 clinical trial of treosulfan, which Medexus announced in June 2022. Among other things, that earlier study demonstrated clinically relevant superiority of treosulfan over a reduced-intensity conditioning busulfan regimen with regard to event-free survival, that study's primary endpoint. Treosulfan is part of a preparative regimen for allogeneic hematopoietic stem cell transplantation, to be used in combination with fludarabine, used in treating eligible patients with acute myeloid leukemia and myelodysplastic syndromes. Final study results and analysis of The pivotal phase 3 clinical trial of Treosulfan conducted by medac GmbH, which was published in the American Journal of Hematology, concluded that the study demonstrates clinically relevant superiority of treos sulfan over a widely applied "reduced-intensity conditioning" busulfan regimen with regard To its primary endpoint, event-free survival. The publication also includes favorable conclusions on two key secondary endpoints, finding that overall survival with treosulfan was superior compared to busulfan and that non-relapse mortality for patients in the treosulfan arm was lower than for patients in the busulfan arm. During the phase 3 clinical trial of treOSulfan, treatment emergent adverse events (TEAEs) were reported by 92.6% of patients in the treosulf an treatment group. Annuncio • Feb 07
Medexus Pharmaceuticals Inc. Announces Board Appointments Medexus Pharmaceuticals welcome Harmony P. Garges MD MPH, Chief Medical Officer of ViiV Healthcare, and Menassie Taddese MBA, former executive at Pfizer and Viatris, to the Medexus board of directors. Dr Garges and Mr Taddese were elected to fill two newly created directorships with effect as of February 6, 2023 and will initially serve until the next annual meeting of Medexus shareholders. Harmony P. Garges MD MPH brings 18 years of multinational pharmaceutical leadership experience in the United States and the UK to the Medexus board. Dr Garges has served as Chief Medical Officer of ViiV Healthcare since August 2019. In this role, Dr Garges is accountable for all aspects of human safety and medical governance and for the global medical affairs strategy and execution for the company. Dr Garges joined ViiV Healthcare in 2016 after spending over a decade at GSK in various leadership roles across R&D, pharmacovigilance, and medical affairs. During her career, Dr Garges has provided medical leadership for over a dozen new drug applications and new product launches. Menassie Taddese MBA is a seasoned veteran of the biopharmaceutical industry with wide ranging experience ingeneral management, finance, business transformation, partnership creation, and overall leadership. He bringsover 26 years of experience leading large commercial and cross-functional organizations across the globe to theMedexus board. Annuncio • Feb 01
Medexus Pharmaceuticals Inc. to Report Q3, 2023 Results on Feb 08, 2023 Medexus Pharmaceuticals Inc. announced that they will report Q3, 2023 results at 4:00 PM, US Eastern Standard Time on Feb 08, 2023 Annuncio • Jan 13
Medexus Pharmaceuticals Inc. Provides Earnings Guidance for the Third Quarter of 2023 Medexus Pharmaceuticals Inc. provided earnings guidance for the third quarter of 2023. For the quarter, the company expected total revenue between $28.5 million and $29.0 million. Annuncio • Dec 20
Medexus Pharmaceuticals Inc. Enters into Exclusive License Agreement with Ethypharm Medexus Pharmaceuticals Inc. announce it has entered into an exclusive license agreement with Ethypharm ("Ethypharm") to register and commercialize Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL ("TH") in the United States. TH is indicated for intra-articular, intrasynovial, or periarticular use in adults and adolescents for the symptomatic treatment of subacute and chronic inflammatory joint diseases, including: rheumatoid arthritis, juvenile idiopathic arthritis (JIA), osteoarthritis and post-traumatic arthritis, synovitis, tendinitis, bursitis and epicondylitis. It is the longest-acting corticosteroid for intra articular injection, often lasting twice as long as competitive products. The companies have agreed to a small upfront fee, which will be funded by Medexus with available liquidity, along with milestone payments at the time of FDA approval, at commercial product launch, and upon certain sales milestones. Medexus will also pay a double-digit royalty to Ethypharm on net sales of TH in the United States. TH has the potential to become the standard of care by offering a longer duration of action along with fewer injections (and by extension, fewer hospital visits and eneral anesthetics), as well as a safer and more cost-effective solution than competitive products. The Company expects to file for FDA approval of TH within 12-24 months. Annuncio • Nov 17
Medexus Pharmaceuticals Inc. Reaches 50% Enrollment Target in Its Phase 4 Clinical Trial Investigating Ixinity® as Prophylactic Treatment for Pediatric Patients Under 12 Years of Age Medexus Pharmaceuticals Inc. announced it has reached the 50% enrollment target in its Phase 4 clinical trial investigating IXINITY® as a prophylactic treatment for pediatric patients under 12 years of age with hemophilia B, a hereditary bleeding disorder characterized by a deficiency of clotting factor IX. IXINITY is an FDA approved intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B. On February 28, 2020, Medexus announced the acquisition of the worldwide rights to the commercial hematology asset, IXINITY®, from Aptevo Therapeutics Inc. In January 2020, Aptevo had already commenced dosing patients in a Phase 4 clinical trial to evaluate the safety and efficacy of IXINITY® in previously treated patients under 12 years of age with hemophilia B. Once completed, this study may support a significant expansion of the indicated patient population for IXINITY®. According to the World Federation of Hemophilia `Report on the Annual Global Survey 2017,' approximately 1 in 3 patients treated for hemophilia B in the U.S. are 12 years of age or younger. Most importantly, look forward to providing this important, additional therapy option to the pediatric population. Previously reported and pooled data from Phase 3 clinical trials demonstrated IXINITY® to be safe and well tolerated in preventing and controlling bleeding episodes in previously treated children under the age of 12 with hemophilia B. Remain determined to advance IXINITY® Phase 4 pediatric clinical trial and look forward to providing further updates as achieve key milestones. Medexus intends to also pursue out-license partners for IXINITY® in markets outside of Canada and the United States. The company will provide further updates as they develop. Annuncio • Nov 10
Medexus Pharmaceuticals Inc. to Report Q2, 2021 Results on Nov 16, 2020 Medexus Pharmaceuticals Inc. announced that they will report Q2, 2021 results at 9:00 AM, Eastern Standard Time on Nov 16, 2020 Annuncio • Sep 26
Medexus Pharmaceuticals Inc. Appoints Michael Pine as Senior Vice President of Business Development and Strategy Medexus Pharmaceuticals Inc. announced the appointment of Michael Pine as Senior Vice President of Business Development and Strategy, effective September 21, 2020. Mr. Pine’s responsibilities include developing Medexus’ product portfolio in both the U.S. and Canada. Mr. Pine is an experienced pharmaceutical industry executive and business leader with a diverse background in both large and small pharmaceutical companies that includes functions in: business development & licensing, M&A, investment banking, business strategy, product marketing, US managed markets, and operations. Most recently, Mr. Pine served as SVP, Business Development & Licensing at Lupin Pharmaceuticals, where he led Lupin's efforts to expand their over $2 billion revenue base further into branded and specialty products with a focus on the North American markets. Prior to that role, Mr. Pine was the VP, Head of Corporate Development & Licensing at Aralez Pharmaceuticals. Mr. Pine also served in a variety of senior roles at companies such as Novartis, Kos Pharmaceuticals, Organon Biosciences, Pfizer, and JP Morgan Chase. Mr. Pine has a BS in Consumer Economics from Cornell University and an MBA from Columbia Business School. Annuncio • Aug 06
Medexus Pharmaceuticals Inc. to Report Q1, 2021 Results on Aug 11, 2020 Medexus Pharmaceuticals Inc. announced that they will report Q1, 2021 results on Aug 11, 2020 Annuncio • Jun 18
Medexus Pharmaceuticals Inc. to Report Fiscal Year 2020 Results on Jun 22, 2020 Medexus Pharmaceuticals Inc. announced that they will report fiscal year 2020 results at 5:00 PM, Eastern Standard Time on Jun 22, 2020